# Key Figures of Consolidated Financial Results for 1st Quarter FY2024

August 2nd, 2024 Sumitomo Chemical Co., Ltd. (Billions of yen)

1. Financial Summary (IFRS)

	Q1 FY2024	Q1 FY2023	Variance	FY2024 (Forecast announced in April)	FY2023
Sales revenue	612.1	563.1	49.0	2,670.0	2,446.9
Core operating income (loss)	5.7	(53.6)	59.3	100.0	(149.0)
Operating income (loss)	11.5	(71.7)	83.2	70.0	(488.8)
Net income (loss) attributable to owners of the parent	24.4	(33.2)	57.5	20.0	(311.8)
Basic earnings (loss) per share	¥ 14.91	¥ (20.27)	¥ 35.18	¥ 12.23	¥ (190.69)
Return on equity	2.5%	(2.8)%	5.3%	2.1%	(29.2)%
Overseas sales revenue	69.2%	65.8%	3.4%	67.8%	68.0%
Exchange rate (yen/\$)	155.85	137.49		145.00	144.59
Naphtha price (yen/kl)	79,000	67,500		75,000	69,100

<sup>\*</sup>Core operating income is a gain and loss concept that reflects recurring earning capacity by deducting gains and losses incurred by non-recurring factors from operating income, which includes the share of profits or losses from investments accounted for using the equity method.

### 2. Sales Revenue / Core Operating Income by Business Segment (IFRS)

(Billions of yen)

		Q1 FY2024	Q1 FY2023	Variance	FY2024 (Forecast announced in April)	FY2023
Essential Chemicals	Sales revenue	201.9	192.4	9.5	900.0	774.0
& Plastics	Core operating income	(20.7)	(21.0)	0.3	(35.0)	(90.7)
Energy & Functional	Sales revenue	68.0	73.4	(5.4)	290.0	300.3
Materials	Core operating income	3.7	3.0	0.7	11.0	7.8
IT-related	Sales revenue	111.5	94.5	17.0	410.0	414.2
Chemicals	Core operating income	18.5	6.7	11.9	47.0	44.0
Health & Crop	Sales revenue	113.3	102.7	10.6	610.0	546.0
Sciences	Core operating income	5.0	(7.0)	12.0	62.0	30.9
DI (; )	Sales revenue	97.9	83.0	14.9	370.0	342.7
Pharmaceuticals	Core operating income	(0.5)	(33.3)	32.7	3.0	(133.0)
011	Sales revenue	19.6	17.3	2.3	90.0	69.8
Others	Core operating income	2.8	2.4	0.4	8.0	8.1
A 11	Sales revenue	_	_	_	_	_
Adjustments	Core operating income	(3.2)	(4.4)	1.2	4.0	(16.1)
T	Sales revenue	612.1	563.1	49.0	2,670.0	2,446.9
Total	Core operating income	5.7	(53.6)	59.3	100.0	(149.0)

# 3. Summary of Consolidated Statement of Income (IFRS)

(Billions of yen)

Variance Ratio
8.7%
_
_
_
_
_
_
_
_
_
_
_
_
_
_

# 4. Summary of Consolidated Statement of Financial Position (IFRS)

(Billions of yen)

						(Dillioi	is of you
	30-Jun-24	31-Mar-24	Variance		30-Jun-24	31-Mar-24	Variance
Current Assets	1,763.5	1,675.9	87.6	Liabilities	2,722.8	2,770.5	(47.6)
Cash and cash equivalents	234.3	217.4	16.8	Trade and other payables	564.3	543.4	21.0
Trade and other receivables	604.6	620.0	(15.4)	Interest-bearing liabilities	1,518.7	1,563.5	(44.8)
Inventories	760.9	709.6	51.3	Others	639.8	663.6	(23.8)
Others	163.8	128.8	35.0	Equity	1,226.9	1,164.4	62.6
Non-current assets	2,186.2	2,258.9	(72.7)	Shareholders' equity	706.4	660.0	46.5
Property, plant and equipment	819.9	796.5	23.4	Other components of equity	316.5	305.8	10.8
Goodwill and intangible assets	561.5	536.7	24.8	Non-controlling interests	203.9	198.6	5.3
Others	804.8	925.7	(120.9)				
Total	3,949.7	3,934.8	14.9	Total	3,949.7	3,934.8	14.9
				Ratio of equity attributable to owners of the parent to total assets	25.9%	24.5%	1.4%
				D/E ratio (times)	1.2	1.3	(0.1)

# 5. Summary of Consolidated Statement of Cash Flows (IFRS)

(Billions of yen)

	Q1 FY2024	Q1 FY2023	Variance	FY2023
Cash flows from operating activities	(12.3)	(131.9)	119.7	(51.3)
Cash flows from investing activities	82.5	(13.4)	95.9	(112.2)
Free cash flows	70.2	(145.4)	215.6	(163.6)
Cash flows from financing activities	(63.0)	142.0	(205.1)	49.2
Others	6.9	19.5	(12.6)	28.7
Increase (decrease) in cash and cash equivalents	14.1	16.2	(2.1)	(85.6)
Cash and cash equivalents at the end of the period	234.3	323.1	(88.9)	217.4

Note: This document has been translated from the Japanese-language original (hereinafter, the "original") for reference purposes only. In the event of any discrepancy between this translated document and the original, the original shall prevail.

The original of Quarterly Consolidated Financial Statements has undergone a review by the Company's audit firm. Please refer to the Japanese review report for details.



August 2, 2024

# Summary of Consolidated Financial Results for First Quarter Fiscal Year 2024 (Under IFRS)

Company name: Sumitomo Chemical Co., Ltd. Listing: Tokyo Stock Exchange

Securities code: 4005

URL: https://www.sumitomo-chem.co.jp/english/
Representative: Keiichi Iwata, Representative Director & President

Inquiries: Shunji Kobayashi, General Manager, Corporate Communications Dept.

Telephone: +81-3-5201-0200

Scheduled date to commence dividend payments:

— Preparation of supplementary material on financial results:

Yes

Holding of financial results briefing:

Yes (for institutional investors and analysts)

(All amounts are rounded to the nearest million yen.)

# 1. Consolidated Financial Results for First Quarter Fiscal Year 2024 (April 1, 2024 to June 30, 2024)

#### (1) Consolidated Operating Results

(Percentages indicate year-on-year changes.)

	Sales rev	enue/	Core operating income			Operating income		Net income		Net income attributable to owners of the parent		Total comprehensive income	
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	
Q1 FY2024	612,144	8.7	5,670	_	11,499	_	33,886	_	24,383	_	69,876	(6.2)	
Q1 FY2023	563,143	(27.3)	(53,598)	_	(71,747)	_	(51,182)	_	(33,153)	l	74,497	(61.3)	

	Basic earnings per share	Diluted earnings per share
	Yen	Yen
Q1 FY2024	14.91	14.90
Q1 FY2023	(20.27)	_

Reference: Share of profit or loss of investments accounted for using the equity method

Q1 FY2024: ¥ (17,352)million Q1 FY2023: ¥ (12,042)million

Income before taxes

Q1 FY2024: ¥ 37,481 million Q1 FY2023: ¥ (49,862)million

#### (2) Consolidated Financial Position

	Total assets	Total equity	Equity attributable to owners of the parent	Ratio of equity attributable to owners of the parent to total assets					
As of	Millions of yen	Millions of yen	Millions of yen	%					
June 30, 2024	3,949,741	1,226,921	1,022,977	25.9					
March 31, 2024	3,934,818	1,164,366	965,753	24.5					

<sup>\*</sup>Core operating income is a gain and loss concept that reflects recurring earning capacity by deducting gains and losses incurred by non-recurring factors from operating income, which includes the share of profits or losses from investments accounted for using the equity method.

<sup>\*</sup>For diluted earnings per share for Q1 FY2023, although there are potential shares, they are not listed because they have an anti-dilutive effect.

#### 2. Dividends

		Dividends per share								
	1st quarter end	2nd quarter end	3rd quarter end	Year- end	Annual					
	Yen	Yen	Yen	Yen	Yen					
FY2023	_	6.00	_	3.00	9.00					
FY2024	_									
FY2024 (Forecast)		3.00	_	6.00	9.00					

Note: Revision of dividend forecasts from the latest announcement: None

# 3. Consolidated Financial Forecasts for Fiscal Year 2024 (April 1, 2024 to March 31, 2025)

(Percentages indicate year-on-year changes.)

	Sales reve	enue	Core operating income income		.' · all ribulable to owners i		Basic earnings per share		
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	Yen
First-half of FY2024	_	_	_	_	_	_		_	
Full-year of FY2024	2,670,000	9.1	100,000	_	70,000	_	20,000	_	12.23

Note: Revision of financial forecasts from the latest announcement: None

#### Notes:

(1) Significant changes in	the scope of consolidation during the	period: None
Newly included:	_	
Excluded:	_	

- (2) Changes in accounting policies and changes in accounting estimates
  - (i) Changes in accounting policies required by IFRS: None
  - (ii) Changes in accounting policies due to other reasons: None
  - (iii) Changes in accounting estimates: None
- (3) Number of shares issued (common shares)
  - (i) Total number of shares issued at the end of the period (including treasury shares)

As of June 30, 2024	1,656,449,145 shares
As of March 31, 2024	1,656,449,145 shares

(ii) Number of treasury shares at the end of the period

As of June 30, 2024	20,504,544 shares
As of March 31, 2024	20,500,922 shares

(iii) Average number of shares outstanding during the period

Three Months ended June 30, 2024	1,635,748,188 shares
Three Months ended June 30, 2023	1,635,216,496 shares

- \* Review of the Japanese-language original of the attached quarterly consolidated financial statements by certified public accountants or an audit firm: Yes (voluntary)
- \* Notes to appropriate use of forecasts and other special items:

Descriptions regarding forward-looking statements about the future performance of the Company contained in this summary are based on information currently available to the Company and certain assumptions judged reasonable and involve risks and uncertainties. The important factors that could cause actual results to differ materially from those discussed in the forward-looking statements include, but are not limited to, general economic conditions in the Company's markets; demand for, and competitive pricing pressure on, the Company's products in the marketplace; rise in prices of raw materials; and fluctuations in foreign exchange rates.

<sup>\*</sup>The consolidated financial forecast for the first-half of FY2024 is not disclosed due to difficulties with predicting.

### Attachments

Summary of Operating Results for First Quarter Fiscal Year 2024	2
(1) Operating Results	2
(2) Consolidated Financial Position ·····	3
(3) Consolidated Forecast and Other Forward-Looking Information	3
2. Consolidated Financial Statements and Major Notes ·····	4
(1) Consolidated Statement of Financial Position	4
(2) Consolidated Statement of Income and  Consolidated Statement of Comprehensive Income	6
(3) Consolidated Statement of Changes in Equity	8
(4) Consolidated Statement of Cash Flows	10
(5) Notes to Consolidated Financial Statements	11
(Framework of Financial Report) ·····	11
(Going Concern Assumption)	11
(Segment Information) ·····	11

#### 1. Summary of Operating Results for First Quarter Fiscal Year 2024

#### (1) Operating Results

For Q1 FY2024, the Group's sales revenue increased by ¥49.0 billion compared to Q1 FY2023, to ¥612.1 billion. In terms of profits and losses, core operating income\* was ¥5.7 billion, operating income was ¥11.5 billion, and net income attributable to owners of the parent was ¥24.4 billion. Results in every category of income improved compared to Q1 FY2023.

\*Core operating income is a gain and loss concept that reflects recurring earning capacity by deducting gains and losses incurred by non-recurring factors from operating income, which includes the share of profits or losses from investments accounted for using the equity method.

The financial results by business segment for Q1 FY2024 are as follows:

#### **Essential Chemicals & Plastics**

Selling prices for synthetic resins, methyl methacrylate and various industrial chemicals increased due to higher raw material prices. As a result, sales revenue increased by ¥9.5 billion from Q1 FY2023, to ¥201.9 billion. There was a deterioration in the financial performance of Rabigh Refining and Petrochemical Company, an affiliated company accounted for by the equity-method, but because of an improvement in market conditions, core operating income was essentially unchanged from Q1 FY2023, with a loss of ¥20.7 billion.

#### **Energy & Functional Materials**

Market conditions for battery metals for cathode materials remained at a low level. In addition, shipments of aluminum declined. On the other hand, shipments of products for automotive-related applications, which had been weak in Q1 FY2023, increased. As a result, sales revenue decreased by ¥5.4 billion from Q1 FY2023, to ¥68.0 billion. Core operating income was ¥3.7 billion, increased by ¥0.7 billion from Q1 FY2023 because of lower fixed costs and other factors.

#### **IT-related Chemicals**

Shipments of display-related materials and processing materials for semiconductors, such as high-purity chemicals and photoresists, increased because of higher demand. As a result, sales revenue increased by ¥17.0 billion from Q1 FY2023, to ¥111.5 billion. Core operating income was ¥18.5 billion, increased by ¥11.9 billion from Q1 FY2023.

#### **Health & Crop Sciences**

Shipments of crop protection products in such locations as North America and India increased. Moreover, market conditions for methionine (feed additives) improved compared to Q1 FY2023. As a result, sales revenue increased by ¥10.6 billion from Q1 FY2023 to ¥113.3 billion. Core operating income was ¥5.0 billion, increased by ¥12.0 billion from Q1 FY2023.

#### **Pharmaceuticals**

In North America, there was an increase in sales of ORGOVYX® (therapeutic agent for advanced prostate cancer), MYFEMBREE® (therapeutic agent for uterine fibroids and endometriosis) and GEMTESA® (therapeutic agent for overactive bladder). On the other hand, in Japan, sales revenues were affected by National Health Insurance (NHI) drug price revisions. As a result, sales revenue increased by ¥14.9 billion from Q1 FY2023, to ¥97.9 billion. Core operating income posted a loss of ¥0.5 billion, improved by ¥32.7 billion from Q1 FY2023, because of increased sales revenue and significant reduction in selling, general and administrative expenses, including a decline in research and development expenses. These reductions resulted from the manifestation of effects of business structure improvement through the restructuring of the Group companies in North America and the selection and concentration of research and development investments.

#### **Others**

In addition to the above five segments, the Group supplies electric power and steam, designs chemical plants and supervises the construction of those facilities, provides transportation and warehousing, and conducts physical property analysis and environmental analysis. Sales revenue of these businesses increased by ¥2.3 billion from Q1 FY2023, to ¥19.6 billion, and core operating income increased by ¥0.4 billion from Q1 FY2023, to ¥2.8 billion.

#### (2) Consolidated Financial Position

As of the end of Q1 FY2024, total assets increased by ¥14.9 billion compared to the end of FY2023, to ¥3,949.7 billion due to the effect of foreign exchange conversions from the weak yen. Mainly inventories increased.

Total liabilities decreased by ¥47.6 billion compared to the end of FY2023, to ¥2,722.8 billion. Interest-bearing liabilities decreased by ¥44.8 billion compared to the end of FY2023, to ¥1,518.7 billion.

Total equity (including non-controlling interests) increased by ¥62.6 billion compared to the end of FY2023, to ¥1,226.9 billion, owing to net income and the increase of exchange differences on conversion of foreign operations resulting from the weak yen. The ratio of equity attributable to the owners of the parent company increased by 1.4 percentage points compared to the end of FY2023, to 25.9%.

#### (3) Consolidated Forecast and Other Forward-Looking Information

There is no change from the consolidated financial forecasts announced on April 30, 2024.

# 2. Consolidated Financial Statements and Major Notes

# (1) Consolidated Statement of Financial Position

Millions of yen	As of June 30, 2024	As of March 31, 2024
Assets		
Current assets:		
Cash and cash equivalents	¥ 234,258	3 ¥ 217,449
Trade and other receivables	604,600	620,022
Other financial assets	55,23	31,338
Inventories	760,915	709,637
Other current assets	93,163	79,077
Subtotal	1,748,167	7 1,657,523
Assets held for sale	15,363	18,359
Total current assets	1,763,530	1,675,882
Non-current assets:		
Property, plant and equipment	819,942	796,526
Goodwill	278,547	263,757
Intangible assets	282,905	5 272,92
Investments accounted for using the equity method	317,363	319,988
Other financial assets	298,795	5 412,747
Retirement benefit assets	110,436	3 110,390
Deferred tax assets	42,211	37,070
Other non-current assets	36,012	2 45,537
Total non-current assets	2,186,21	2,258,936
Total assets	¥ 3,949,74°	¥ 3,934,818

Millions of yen As of June 30, 2024 As of March 31, 2024

Liabilities and equity				
Liabilities				
Current liabilities:				
Bonds and borrowings	¥	566,734	¥	585,905
Trade and other payables		564,337		543,384
Other financial liabilities		78,967		77,610
Income taxes payable		29,207		8,545
Provisions		98,118		90,919
Other current liabilities		105,007		129,087
Subtotal		1,442,370		1,435,450
Liabilities directly associated with assets held for sale		18,225		8,037
Total current liabilities		1,460,595		1,443,487
Non-current liabilities:				
Bonds and borrowings		951,999		977,581
Other financial liabilities		100,562		100,144
Retirement benefit liabilities		30,832		30,589
Provisions		32,384		46,059
Deferred tax liabilities		100,480		121,146
Other non-current liabilities		45,968		51,446
Total non-current liabilities		1,262,225		1,326,965
Total liabilities		2,722,820		2,770,452
Equity				
Share capital		89,938		89,938
Capital surplus		213		237
Retained earnings		624,651		578,175
Treasury shares		(8,356)		(8,355)
Other components of equity		316,649		304,033
Other comprehensive income associated with assets held for sale		(118)		1,725
Equity attributable to owners of the parent		1,022,977		965,753
Non-controlling interests		203,944		198,613
Total equity		1,226,921		1,164,366
Total liabilities and equity	¥	3,949,741	¥	3,934,818

# (2) Consolidated Statement of Income and Consolidated Statement of Comprehensive Income

### **Consolidated Statement of Income**

First quarter ended June 30, 2024 and 2023

Millions of yen		Q1 FY2024	Q1 FY2023			
Sales revenue	¥	612,144	¥	563,143		
Cost of sales		(440,306)		(434,011)		
Gross profit		171,838		129,132		
Selling, general and administrative expenses		(151,235)		(178,072)		
Other operating income		13,632		10,135		
Other operating expenses		(5,384)		(20,900)		
Share of profit (loss) of investments accounted for using the equity method		(17,352)		(12,042)		
Operating income (loss)		11,499		(71,747)		
Finance income		40,162		39,171		
Finance expenses		(14,180)		(17,286)		
Income (loss) before taxes		37,481		(49,862)		
Income tax expenses		(3,595)		(1,320)		
Net income (loss)		33,886		(51,182)		
Net income (loss) attributable to:						
Owners of the parent		24,383		(33,153)		
Non-controlling interests		9,503		(18,029)		
Net income (loss)	¥	33,886	¥	(51,182)		

Yen	Q1 FY2024	Q1 FY2023
Earnings per share:		
Basic earnings (loss) per share	14.91	(20.27)
Diluted earnings per share	14.90	_

# **Consolidated Statement of Comprehensive Income**

First quarter ended June 30, 2024 and 2023

Millions of yen	C	21 FY2024	Q1 FY2023			
Net income (loss)	¥	33,886	¥	(51,182)		
Other comprehensive income:						
Items that will not be reclassified to profit or loss						
Remeasurements of financial assets measured at fair value through other comprehensive income		(5,376)		36,468		
Remeasurements of defined benefit plans		(7)		(5)		
Share of other comprehensive income of investments accounted for using the equity method		981		407		
Total items that will not be reclassified to profit or loss		(4,402)		36,870		
Items that may be subsequently reclassified to profit or loss						
Cash flow hedge		387		816		
Exchange differences on conversion of foreign operations		29,117		81,672		
Share of other comprehensive income of investments accounted for using the equity method		10,888		81,672 6,321		
Total items that may be subsequently reclassified to profit or loss		40,392		88,809		
Other comprehensive income, net of taxes		35,990		125,679		
Total comprehensive income		69,876		74,497		
Total comprehensive income attributable to:						
Owners of the parent		62,157		63,422		
Non-controlling interests		7,719		11,075		
Total comprehensive income	¥	69,876	¥	74,497		

# (3) Consolidated Statement of Changes in Equity First quarter ended June 30, 2024

	Equity attributable to owners of the parent												
									Ot	her compor	nent	ts of equity	
Millions of yen		Share capital		Capital surplus	-	Retained earnings		reasury shares	asse a th	neasurements of financial ets measured t fair value rough other mprehensive income		measurements defined benefit plans	
Balance as of April 1, 2024	¥	89,938	¥	237	¥	578,175	¥	(8,355)	¥	83,448	¥	_	
Net income (loss)		_		_		24,383		_		_		_	
Other comprehensive income		_		_		_		_		(623)		274	
Total comprehensive income		_		_		24,383		_		(623)		274	
Purchase of treasury shares		-		_		_		(1)		_		_	
Disposal of treasury shares		-		(0)		_		0		_		_	
Dividends		_		_		(4,908)		_		_		_	
Changes resulting from loss of control of subsidiaries Change in interest due to		_		_		_		_		_		_	
transactions with non-controlling interests		_		(24)		_		_		_		_	
Transfer from other components of equity to retained earnings Transfer to other comprehensive		_		_		27,001		_		(26,727)		(274)	
income associated with assets held for sale		_		_		_		_		_		_	
Total transactions with owners		_		(24)		22,093		(1)		(26,727)		(274)	
Balance as of June 30, 2024	¥	89,938	¥	213	¥	624,651	¥	(8,356)	¥	56,098	¥	_	

	Equity attributable to owners of the parent													
		Other	com	ponents of	eq	uity		Other				Non-		
		ash flow edges	diff co	exchange ferences on nversion of foreign operations		Total	as	mprehensive income sociated with sets held for sale	attı to c	Equity ributable owners of e parent		ontrolling nterests	Total equity	
Balance as of April 1, 2024	¥	319	¥	220,266	¥	304,033	¥	1,725	¥	965,753	¥	198,613	¥1,164,366	
Net income (loss)		_		_		_		_		24,383		9,503	33,886	
Other comprehensive income		387		39,461		39,499		(1,725)		37,774		(1,784)	35,990	
Total comprehensive income		387		39,461		39,499		(1,725)		62,157		7,719	69,876	
Purchase of treasury shares		_		_		_		_		(1)		_	(1)	
Disposal of treasury shares		_		_		_		_		0		_	0	
Dividends		_		_		_		_		(4,908)		(2,440)	(7,348)	
Changes resulting from loss of control of subsidiaries Change in interest due to		_		_		_		_		_		28	28	
transactions with non-controlling interests		_		_		_		_		(24)		24	-	
Transfer from other components of equity to retained earnings Transfer to other comprehensive		_		_		(27,001)		_		_		_	_	
income associated with assets held for sale		_		118		118		(118)		_		_	_	
Total transactions with owners				118		(26,883)		(118)		(4,933)		(2,388)	(7,321)	
Balance as of June 30, 2024	¥	706	¥	259,845	¥	316,649	¥	(118)	¥1	,022,977	¥	203,944	¥1,226,921	

				Equit	y at	tributable to	ow	ners of the	е ра	arent		
									0	ther compor	ent	s of equity
Millions of yen		Share capital		Capital surplus	-	Retained earnings		easury hares	ass ass th	neasurements of financial ets measured at fair value brough other mprehensive income		neasurements lefined benefit plans
Balance as of April 1, 2023	¥	89,810	¥	_	¥	891,552	¥	(8,349)	¥	81,869	¥	
Net income (loss)		_		_		(33,153)		_		_		_
Other comprehensive income		_		_		_		_		21,714		10
Total comprehensive income		_		_		(33,153)		_		21,714		10
Purchase of treasury shares		_		_		_		(1)		_		_
Disposal of treasury shares		_		0		_		0		_		_
Dividends		_		_		(9,812)		_		_		_
Changes resulting from loss of control of subsidiaries		_		_		349		_		_		_
Change in interest due to transactions with non-controlling interests		_		_		_		_		_		_
Transfer from other components of equity to retained earnings		_		_		5,366		_		(5,356)		(10)
Transfer to other comprehensive income associated with assets held for sale		_		_		_		_		_		_
Total transactions with owners		_		0		(4,097)		(1)		(5,356)		(10)
Balance as of June 30, 2023	¥	89,810	¥	0	¥	854,302	¥	(8,350)	¥	98,227	¥	

			Eq	uity attribut								
		Other of	com	ponents of	eq	uity		Other			Non-	
		ash flow edges	diff	exchange erences on nversion of foreign perations		Total	as	omprehensive income ssociated with ssets held for sale	Equity attributable to owners of the parent	controlling interests		Total equity
Balance as of April 1, 2023	¥	(539)	¥	116,500	¥	197,830	¥	349	¥1,171,192	¥	317,997	¥1,489,189
Net income (loss)		_		_		_		_	(33,153)		(18,029)	(51,182)
Other comprehensive income		869		73,982		96,575		_	96,575		29,104	125,679
Total comprehensive income		869		73,982		96,575		_	63,422		11,075	74,497
Purchase of treasury shares		_		_		_		_	(1)		_	(1)
Disposal of treasury shares		_		_		_		_	0		_	0
Dividends		_		_		_		_	(9,812)		(3,934)	(13,746)
Changes resulting from loss of control of subsidiaries Change in interest due to		_		_		_		(349)	_		_	_
transactions with non-controlling interests		_		_		_		_	-		_	_
Transfer from other components of equity to retained earnings Transfer to other comprehensive		_		_		(5,366)		_	_		-	_
income associated with assets held for sale		_		_		_		_	_		_	
Total transactions with owners						(5,366)		(349)	(9,813)		(3,934)	(13,747
Balance as of June 30, 2023	¥	330	¥	190,482	¥	289,039	¥	′ –	¥1,224,801	¥	325,138	¥1,549,939

# **(4) Consolidated Statement of Cash Flows** First quarter ended June 30, 2024 and 2023

Millions of yen	Q	1 FY2024	Q <sup>2</sup>	I FY2023
Cash flows from operating activities:				
Income (loss) before taxes	¥	37,481	¥	(49,862)
Depreciation and amortization		33,569		39,300
Share of (profit) loss of investments accounted for using the equity method		17,352		12,042
Interest and dividend income		(6,589)		(5,581)
Interest expenses		7,425		6,784
Restructuring costs		3,533		19,297
(Gain) loss on sale of property, plant and equipment, and intangible assets		(10,135)		(725)
(Increase) decrease in trade receivables		35,473		53,451
(Increase) decrease in inventories		(39,931)		(34,127)
Increase (decrease) in trade payables		3,782		(22,303)
Increase (decrease) in unearned revenue		(2,961)		(2,927)
Increase (decrease) in provisions		1,268		(35,791)
Others, net		(76,316)		(82,192)
Subtotal		3,951		(102,634)
Interest and dividends received		10,643		9,034
Interest and dividends reserved		(7,808)		(6,875)
Income taxes paid		(8,104)		(30,749)
Restructuring costs paid		(10,940)		(694)
Net cash provided by (used in) operating activities  Cash flows from investing activities:		(12,258)		(131,918)
<u>c</u>		(0.454)		(4.500)
Net (increase) decrease in securities		(3,454)		(4,599)
Purchase of property, plant and equipment, and intangible assets		(36,076)		(44,188)
Proceeds from sales of property, plant and equipment, and intangible assets		12,242		430
Proceeds from sales of subsidiaries		_		11,074
Payments for sales of subsidiaries		(3,911)		
Purchase of other financial assets		(902)		(2,343)
Proceeds from sales and redemption of other financial assets		113,633		24,788
Others, net		962		1,399
Net cash provided by (used in) investing activities		82,494		(13,439)
Cash flows from financing activities:				
Net increase (decrease) in short-term borrowings		(21,922)		79,406
Net increase (decrease) in commercial paper		18,000		53,000
Proceeds from long-term borrowings		34		29,956
Repayments of long-term borrowings		(36,718)		(1,815)
Redemption of bonds		(10,000)		_
Repayments of finance lease liabilities		(4,550)		(4,340)
Cash dividends paid		(4,919)		(9,821)
Cash dividends paid to non-controlling interests		(2,441)		(3,888)
Others, net		(524)		(450)
Net cash provided by (used in) financing activities		(63,040)		142,048
Effect of exchange rate changes on cash and cash equivalents		6,862		19,464
Increase (decrease) in cash and cash equivalents		14,058		16,155
Cash and cash equivalents at the beginning of the year		217,449		305,844
Net increase (decrease) in cash and cash equivalents resulting from transfer to assets held for sale		2,751		1,135
Cash and cash equivalents at the end of the period	¥	234,258	¥	323,134
. '		,		, -

#### (5) Notes to Consolidated Financial Statements

#### Framework of Financial Report

The Group's quarterly consolidated financial statements are prepared in accordance with Article 5, Paragraph 2 of the Tokyo Stock Exchange, Inc.'s Standards for the Preparation of Quarterly Financial Statements, applying the omitted disclosures as set forth in Article 5, Paragraph 5 of the Standards for the Preparation of Quarterly Financial Statements.

#### **Going Concern Assumption**

Not applicable.

#### **Segment Information**

#### 1. Reportable Segments

The reportable segments of the Group refer to business units for which separate financial information is available and that are reviewed regularly at the Board of Directors meeting in order to determine the allocation of management resources and evaluate the business performance of each business unit.

The Group divides its operations into business sectors identified by products and services, which manage manufacturing, sales, and research in an integrated manner. Each business sector is responsible for developing comprehensive domestic and overseas strategies with respect to its products and services, and operates its business activities.

Accordingly, the Group has five reportable segments based on its products and services in accordance with its business sectors, including "Essential Chemicals & Plastics," "Energy & Functional Materials," "IT-related Chemicals," "Health & Crop Sciences," and "Pharmaceuticals."

The major products and services of each reportable segment are as follows:

Reportable Segment	Major Products and Services
Essential Chemicals & Plastics	Synthetic resins, raw materials for synthetic fibers, various industrial chemicals, methyl methacrylate products, synthetic resin processed products, etc.
Energy & Functional Materials	Alumina, aluminum, specialty chemicals, additives, synthetic rubber, engineering plastics, battery materials, etc.
IT-related Chemicals	Optical products, semiconductor processing materials, compound semiconductor materials, touch screen sensor panels, etc.
Health & Crop Sciences	Crop protection chemicals, fertilizers, agricultural materials, household insecticides, products for control of infectious diseases, feed additives, active pharmaceutical ingredients and intermediates, etc.
Pharmaceuticals	Pharmaceuticals for medical treatment, radiopharmaceuticals, etc.

#### 2. Reportable Segment Information

The accounting methods for each reportable segment are, in principle, identical to those used in the consolidated financial statements. The segment profit or loss is core operating income, which is calculated from operating income after excluding effects from non-recurring factors.

Inter-segment sales revenue is based on market prices.

#### First Quarter Fiscal Year 2024

Millions of yen	Ch	ssential emicals & Plastics	Fu	nergy & unctional laterials		related nemicals		Health & Crop Sciences		harma- euticals	Total		Others (Note 1)		justments Note 2)	Consoli- dated
Sales revenue:																
Sales revenues from external customers	¥	201,893	¥	67,989	¥	111,471	¥	113,314	¥	97,917 ¥	592,584	¥	19,560	¥	- ¥	612,144
Inter-segment sales revenues		1,509		4,214		118		361		1	6,203		18,714		(24,917)	_
Total sales revenue		203,402		72,203		111,589		113,675		97,918	598,787		38,274		(24,917)	612,144
Segment profit (loss) : core operating income (loss)	¥	(20,701)	¥	3,745	¥	18,549	¥	4,962	¥	(541) ¥	6,014	¥	2,832	¥	(3,176) ¥	5,670

Note 1: "Others" represents businesses such as supplying electrical power and steam, providing services for the design, engineering, and construction management of chemical plants, providing transport and warehousing, and conducting materials and environmental analysis, which are not included in reportable segments.

Note 2: ¥(3,176) million for segment profit (loss) in "Adjustments" includes inter-segment elimination of ¥329 million and corporate expenses of ¥(3,505) million unallocated to each reportable segment. Corporate expenses are mainly research and development expenses for company-wide research, which are not attributed to reportable segments.

#### First Quarter Fiscal Year 2023

Millions of yen	Ch	ssential emicals & Plastics	Fι	nergy & unctional laterials		-related emicals		Health & Crop Sciences		Pharma- ceuticals	Total		Others Note 1)		justments Note 2)	Consoli- dated
Sales revenue:																
Sales revenues from external customers	¥	192,353	¥	73,383	¥	94,451	¥	102,707	¥	82,985 ¥	545,879	¥	17,264	¥	– ¥	563,143
Inter-segment sales revenues		1,361		5,466		110		762		1	7,700		20,164		(27,864)	_
Total sales revenue		193,714		78,849		94,561		103,469		82,986	553,579		37,428		(27,864)	563,143
Segment profit (loss) : core operating income (loss)	¥	(21,005)	¥	3,004	¥	6,669	¥	(7,049)	¥	(33,273) ¥	(51,654)	¥	2,430	¥	(4,374) ¥	(53,598)

Note 1: "Others" represents businesses such as supplying electrical power and steam, providing services for the design, engineering, and construction management of chemical plants, providing transport and warehousing, and conducting materials and environmental analysis, which are not included in reportable segments.

Note 2: ¥(4,374) million for segment profit (loss) in "Adjustments" includes inter-segment elimination of ¥5 million and corporate expenses of ¥(4,379) million unallocated to each reportable segment. Corporate expenses are mainly research and development expenses for company-wide research, which are not attributed to reportable segments.

Adjustments to income (loss) before taxes from core operating income (loss) were as follows:

Millions of yen	Q1	FY2024	Q1	1 FY2023		
Core operating income (loss)	¥	5,670	¥	(53,598)		
Gains on sales of property, plant and equipment, and intangible assets		10,135		725		
Restructuring costs		(3,533)		(19,297)		
Changes in fair value of contingent consideration		(78)		(38)		
Others, net		(695)		461		
Operating income (loss)		11,499		(71,747)		
Finance income		40,162		39,171		
Finance expenses		(14,180)		(17,286)		
Income (loss) before taxes	¥	37,481	¥	(49,862)		